IP Library Granted Patent US 10,258,575
Granted Patent B2
US 10,258,575 · App. 16/028,305 · Granted Apr 16, 2019

Oral drug dosage forms having desired drug release profiles and uses thereof

Inventor: Xiaoling Li (Dublin, CA)
Assignee: Triastek, Inc.
A61K9/2031A61K9/209A61K9/2027A61K9/2072A61K31/192
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,258,575
App. No.
16/028,305
Granted
Apr 16, 2019
Kind
B2
Abstract

The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Claims (33)

1. An oral drug dosage form comprising:

a) a column core having a top surface and a bottom surface,

wherein the column core comprises at least two vertical segments in direct contact with each other, each comprising a different drug embedded in a substrate; and

b) a shell wrapping around the column core,

wherein the shell is in direct contact with the at least two segments and leaves the top, bottom, or both surfaces exposed,

wherein the shell has a slower dissolution rate than the substrate in the column core, and

wherein upon exposure to gastrointestinal fluid the shell blocks the interface between the segments and the gastrointestinal fluid, and the drugs in the at least two vertical segments are simultaneously released through the exposed surface.

2. The oral drug dosage form of claim 1 , wherein the shell is water insoluble.

3. The oral drug dosage form of claim 1 , wherein the substrate in each of the at least two vertical segments are the same.

4. The oral drug dosage form of claim 1 , wherein the substrate in each of the at least two vertical segments are different from each other.

5. The oral drug dosage form of claim 4 , wherein the drugs in the at least two different vertical segments are released at different rates.

6. The oral drug dosage form of claim 1 , wherein the column core comprises at least three vertical segments.

7. The oral drug dosage form of claim 6 , wherein the at least three vertical segments are pie-shaped.

8. The oral drug dosage form of claim 1 , wherein only the top surface of the column core is exposed.

9. The oral drug dosage form of claim 1 , wherein both the top surface and bottom surface of the column core are exposed.

10. The oral drug dosage form of claim 1 , wherein the drugs in the at least two different vertical segments are released according to a zero-order release profile.

11. The oral drug dosage form of claim 1 , wherein the drug in the at least two different vertical segments are released according to a first-order release profile.

12. The oral drug dosage form of claim 1 , wherein the drug in one of the at least two different vertical segments is released according to a zero-order release profile, and wherein the drug in another one of the at least two different vertical segments are released according to a first-order release profile.

13. The oral dosage form of claim 1 , wherein the substrate is made of a thermoplastic material.

14. An oral drug dosage form comprising:

a) a column core comprising a drug having a top surface and a bottom surface,

wherein the column core comprises at least two vertical segments in direct contact with each other, each comprising the drug embedded in a different substrate; and

b) a shell wrapping around the column core,

wherein the shell is in direct contact with the at least two segments and leaves the top, bottom, or both surfaces exposed,

wherein the shell has a slower dissolution rate than the substrate in the column core;

wherein upon exposure to gastrointestinal fluid the shell blocks the interface between the segments and the gastrointestinal fluid and the drugs in the at least two vertical segments are simultaneously released through the exposed surface, and

wherein the drugs in the at least two different vertical segments are released at different rates.

15. The oral drug dosage form of claim 14 , wherein the shell is water insoluble.

16. The oral drug dosage form of claim 14 , wherein the column core comprises at least three vertical segments.

17. The oral drug dosage form of claim 16 , wherein the at least three vertical segments are pie-shaped.

18. The oral drug dosage form of claim 14 , wherein only the top surface of the column core is exposed.

19. The oral drug dosage form of claim 14 , wherein both the top surface and bottom surface of the column core are exposed.

20. The oral dosage form of claim 14 , wherein the substrate is made of a thermoplastic material.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2018
From: LI, XIAOLING
To: TRIASTEK, INC.
Reel/Frame 046781/0986 →
Continuity (5)
Continuation 15173596 · Jun 3, 2016
Provisional Application 62313092 · Mar 24, 2016
Provisional Application 62296087 · Feb 17, 2016
Provisional Application 62170645 · Jun 3, 2015
Related Publication 20180311167A1 · Nov 1, 2018
Cited By (10)
US 12,246,022 US 12,280,048 US 12,324,856 US 12,357,611 US 12,384,112 US 12,472,178 US 12,492,167 US 12,595,084 US 12,605,881 US 12,678,422